IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Investor Presentation
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IOL Chemicals and Pharmaceuticals shared its Q3 & 9M FY26 investor presentation, showing Q3 revenue of ₹580.4 Cr (up 10.9% YoY) and EBITDA of ₹62.6 Cr (up 22.8% YoY) with margins expanding to 10.7% from 9.7% a year ago. For 9M FY26, revenue rose 9.6% YoY to ₹1,699.6 Cr while EBITDA grew 24.8% to ₹196.1 Cr, pushing margin to 11.4% (vs 10.0%). The company booked an exceptional item of ₹11.2 Cr for new labour code provisions, and reported a debt-to-equity ratio of just 0.07. Management highlighted a shift in pharma mix from 82% Ibuprofen in FY21 to 66% in FY25, Paracetamol capacity of 10,800 MTPA, and 101 acres of newly acquired land for future expansion. The export share target is to grow to ~40%, supported by 15 USFDA DMFs and 19 approved CEPs.
Strong margin expansion, a near-debt-free balance sheet, and clear diversification beyond Ibuprofen are positives for shareholders. The ₹11.2 Cr exceptional charge is a one-time hit, and the continued capacity additions and export push could support earnings growth over the next 2-3 years.